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In April 2009, 2 cases of respiratory illness reported to the Centers for Disease Control and Prevention (CDC) were determined to be caused by a novel influenza virus. 1 Beginning in June 2009, state and local health departments (LHDs) worked with the federal government to implement a pandemic response based, in part, on previously developed pandemic response plans. The 2009 H1N1 vaccination program was a public-private partnership: The federal government provided vaccine to states at no cost, so providers were not permitted to bill third-party payers for the vaccine itself; however, private providers could bill for vaccine administration. 4 Government health programs including Medicare, Medicaid, TRICARE, and the Veterans' Administration, and many private health insurers, covered the cost of 2009 H1N1 vaccine administration for beneficiaries.
Initially, it was unclear whether public providers like LHDs would be permitted to bill administration fees. Multiple rounds of the CDC's Public Health Emergency Response (PHER) funding were made available to states to support implementation of H1N1 vaccination programs; states could allocate PHER funds to LHDs at their discretion. Because PHER funding amounts were initially unknown, some LHDs expressed concern about having adequate funds for H1N1 vaccination programs if they could not bill for vaccine administration. Ultimately billing of third-party payers was permitted, although LHDs were required to vaccinate all persons regardless of ability to pay. 5 The National Association of County and City Health Officials, in collaboration with the CDC, conducted a survey to understand policies and strategies used by LHDs during the pandemic response. This report describes the prevalence of billing and factors associated with billing for 2009 H1N1 vaccine administration.
• Methods
Survey
A nationally representative sample was selected from all US LHDs (N = 2794) using stratified random sampling with replacement from 7 strata based on service population size. Local health departments in the largest population stratum (serving ≥1 million people) were oversampled; 527 LHDs were selected. Of 527 sampled LHDs, 336 (64%) responded. Of these, 28 LHDs were excluded for high item nonresponse, leaving 308 surveys (58%) for analysis. Responding LHDs represented 45 states, with 1 to 20 LHDs per state. Results were weighted to account for sampling scheme and differences in nonresponse by stratum. Unweighted frequencies and weighted proportions are presented.
Interviews
Independent of the survey, the CDC contacted a convenience sample of LHDs known to have billed for 2009 H1N1 vaccine administration. Between February and November 2010, the author conducted semistructured telephone interviews with 9 LHDs using a standardized list of questions, including which payers were billed and in which settings, prior experience billing for vaccinations and how this informed billing activities for 2009 H1N1 vaccine, how insurance information was collected and processed, estimated proportions of vaccinations billed for which claims were paid, and barriers and facilitators to billing for 2009 H1N1 vaccine administration. After each interview, the author provided a written summary to the LHD for review. Common themes are presented later.
• Results
Survey
Prior to the 2009-2010 influenza pandemic, most (82%) responding LHDs offering seasonal influenza vaccine had billed third-party payers for influenza vaccine administration. However, only 20% (n = 57) of the 297 respondents that offered 2009 H1N1 vaccine reported billing for its administration (the Table) . Among those 57 LHDs, the most commonly billed payers were Medicare (74%) and Medicaid (80%); 55% billed one or more private insurance plans. A majority of LHDs billing for 2009 H1N1 vaccine administration billed for vaccines given at public health department clinics (80%) and community mass vaccination events (51%); nearly half (46%) also billed for administering vaccines at schoollocated vaccination clinics (the Table ) . Roster billingsubmitting a single claim for multiple beneficiaries--was reported by only 37% of billing LHDs, primarily for Medicare billing. Nearly one-third of LHDs billing for 2009 H1N1 vaccine administration did not know whether roster billing was used.a (continued)% (n) In bivariate analysis, billing for 2009 H1N1 vaccine administration was more common among LHDs that previously offered seasonal influenza vaccination (21% vs 3%, P = .003), previously billed for seasonal influenza vaccination (23% vs 11%, P = .04), and previously conducted school-located influenza vaccination clinics (30% vs 14%, P = .002). No difference in 2009 H1N1 billing practices was observed among LHDs serving different population sizes. Local health departments serving fewer than 50 000 people were more likely than those serving midsize populations to have billed Medicare for seasonal influenza vaccination prior to the 2009-2010 season (97% vs 87%, P = .01).
Interviews
All LHDs interviewed had prior billing experience. 2009 H1N1 billing practices varied; some LHDs billed only insurance plans with which billing arrangements already existed, others established relationships with additional plans to bill for 2009 H1N1 vaccine administration. Methods for collecting and processing insurance information also varied, although several LHDs described using existing electronic systems to facilitate creation and submission of insurance claims. Most LHDs estimated 70% to 90% of claims submitted for 2009 H1N1 vaccine administration were paid, although some claims had yet to be processed by the insurance plans billed. Factors cited as facilitating billing for 2009 H1N1 vaccine administration included prior billing experience, contracting with organizations familiar with insurance billing or hiring staff specifically for billing, and providing billing training to existing staff. Factors cited as barriers included variable benefits coverage and billing practices among private insurers, the need to revise existing systems to accommodate 2009 H1N1 vaccine billing, and difficulty understanding the CDC's billing guidance.
• Comment Among LHDs that did bill for 2009 H1N1 vaccine administration, billing was broadly implemented, with many LHDs reporting in the survey and interviews billing both public and private payers and billing in a variety of settings. Interviews with LHDs that billed for 2009 H1N1 vaccine administration indicated systems used to collect and process insurance information were generally successful, and most LHDs felt billing efforts had been worthwhile. These findings suggest that, once established, billing practices may be used for a variety of insurers and settings. However, some LHDs interviewed were unsure whether they would continue additional billing efforts in the 2010-2011 influenza season, primarily due to resource concerns.
Study results are subject to certain limitations and may not be generalizable to LHDs nationally. Local health departments responding to the survey may differ from nonresponders in ways that were unmeasured.
Nonresponse weighting can reduce but not eliminate potential bias. Second, interview data were gathered only from a small number of LHDs. Finally, the extent of private insurance billing cannot be fully quantified as survey respondents were asked whether they billed private insurance but not the number of plans billed.
During the 2009-2010 influenza season, survey data indicate LHDs that billed for 2009 H1N1 vaccination utilized billing processes across a variety of insurance plans and settings. However, few LHDs responding to the survey chose to bill for 2009 H1N1 vaccine administration despite prior experience. Previous billing experience may reduce the level of effort needed to establish or amend billing relationships with insurance plans, but billing remains a challenge for LHDs. 6 Beginning with the American Recovery and Reinvestment Act of 2009, several states have received funding for planning and developing vaccination billing processes in state and LHDs. 7 Continuing to develop public health billing capacity for influenza vaccination and other vaccines for children and adults will allow LHDs to recoup the costs of vaccinating insured persons, 8 and may also prepare them to bill for routine services and during future public health emergencies.
